PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

BACKGROUND: Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Analysis of circulating tumor DNA (ctDNA) provides a minimally invasive approach to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumbrava, E.E., Call, S.G., Huang, H.J., Stuckett, A.L., Madwani, K., Adat, A., Hong, D.S., Piha-Paul, S.A., Subbiah, V., Karp, D.D., Fu, S., Naing, A., Tsimberidou, A.M., Moulder, S.L., Koenig, K.H., Barcenas, C.H., Kee, B.K., Fogelman, D.R., Kopetz, E.S., Meric-Bernstam, F., Janku, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414046/
https://www.ncbi.nlm.nih.gov/pubmed/34479035
http://dx.doi.org/10.1016/j.esmoop.2021.100230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414046/
https://www.ncbi.nlm.nih.gov/pubmed/34479035
http://dx.doi.org/10.1016/j.esmoop.2021.100230

Ejemplares similares